Clinical trials: Age Related Maculopathy
Age Related Macular Degeneration
High-Resolution Ultrasound Imaging of the Retina and Choroid for Detection on Age Related Macular Degeneration
The macula is the site of central vision within the retina. The retina is oxygenated by the underlying choroid. These tissues are less than 1 mm thick in total.
- Trial name
- NCT00277784
- Testing
- Ultrasound examination
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Age-Related Macular Degeneration
Proton Radiation Therapy for Macular Degeneration
This is a pilot study to determine if proton radiation therapy can provide effective and safe treatment for subfoveal neovascularization membrane (SNVM).
- Trial name
- NCT01833325
- Testing
- Proton radiation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Florida
Macular Degeneration
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
This is a Phase III, open-label, multicenter extension study of intravitreally administered ranibizumab in subjects with primary or recurrent subfoveal choroidal neovascularization (CNV) secondary to AMD who have completed the…
- Trial name
- NCT00095433
- Testing
- rhuFab V2 (ranibizumab)
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Age Related Macular Degeneration (AMD), Age Related Macular Degeneration
Evaluating the Relationship Between Function and Structure Using Data From a GA Natural History Cohort
Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration that leads to progressive and irreversible vision loss.
- Conditions
- Age Related Macular Degeneration (AMD), Age Related Macular Degeneration, AMD, Geographic Atrophy
- Trial name
- ARCHERY (NCT07424235)
- Volunteers
- 60 people
- Sponsor
- IRCCS Ospedale San Raffaele
Retinitis Pigmentosa, Maculopathy, Age Related
High Resolution, High-speed Multimodal Ophthalmic Imaging
Knowledge of the pathogenesis of ocular conditions, a leading cause of blindness, has benefited greatly from recent advances in ophthalmic imaging.
- Conditions
- Retinitis Pigmentosa, Maculopathy, Age Related, Macular Dystrophy, Macular Edema
- Trial name
- IMA-MODE (NCT04129021)
- Testing
- High-resolution retinal imaging through adaptive optics, High-resolution retinal imaging through holographic systems
- Where
- France
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Macular Degeneration
Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy
This study will determine whether the drug celecoxib (Celebrex® (Registered Trademark)) can help stabilize or improve vision in patients with age-related macular degeneration (AMD) who are receiving photodynamic therapy, or PDT…
- Trial name
- NCT00043680
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Eye Institute (NEI)
Age-Related Macular Degeneration
A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
The purpose of this study was to compare the development of new geographic atrophy in patients with wet Age-related Macular Degeneration (AMD) when treated with either ranibizumab or aflibercept over 24 months.
- Trial name
- RIVAL (NCT02130024)
- Testing
- Ranibizumab 0.5 mg, Aflibercept 2.0 mg
- Where
- 22 sites in Australia
- Volunteers
- 281 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
Long-Term Follow Up of VOY-101 Non-nAMD Extension Study
Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration
- Trial name
- OASIS (NCT07660640)
- Testing
- observational study, VOY-101
- Where
- 4 sites in United States, Israel
- Volunteers
- 88 people
- Sponsor
- Perceive Biotherapeutics, Inc.
Age-related Macular Degeneration
Genetic Load and Phenotype in Aggressive AMD
Patients with AMD will provide cheek cell samples to determine if their is a correlation between genotype (DNA markers) and phenotype (the type of AMD the patient has).
- Trial name
- RPED Genetics (NCT01650948)
- Testing
- RetnaGene AMD LDT
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Sequenom, Inc.
Neovascular Age-related Macular Degeneration
Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
This is a randomized, double-masked, multicenter study to evaluate the efficacy and safety of FYB203 compared to Eylea® in patients with neovascular age related macular degeneration.
- Trial name
- MAGELLAN-AMD (NCT04522167)
- Testing
- FYB203 (Proposed aflibercept biosimilar), Eylea® (Aflibercept)
- Where
- 66 sites in Bulgaria, Czechia and 7 more
- Volunteers
- 434 people
- Sponsor
- Bioeq GmbH
Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
- Trial name
- Super Tuscan (NCT07205887)
- Testing
- Remigromig, Aflibercept 2.0 mg
- Where
- 55 sites in United States
- Volunteers
- 160 people
- Sponsor
- EyeBiotech Ltd.
Age-related Macular Degeneration (ARMD), Choroidal Neovascularization
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly…
- Conditions
- Age-related Macular Degeneration (ARMD), Choroidal Neovascularization, Anti-vascular Endothelial Growth Factor
- Trial name
- NCT07187804
- Testing
- Intravitreal faricimab injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Kim's Eye Hospital
Pigment Epithelial Detachment
iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
LT1009-Oph-002 is a Phase 1b study designed to evaluate the safety and potential efficacy of iSONEP following one, two or three injections of iSONEP, as needed, for the treatment of Pigment Epithelial Detachment (PED) secondary…
- Trial name
- PED (NCT01334255)
- Testing
- iSONEP (sonepcizumab/LT1009)
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Lpath, Inc.
Geographic Atrophy
Pterygopalatine Ganglion Stimulation for the Treatment of Geographic Atrophy
The goal of this clinical trial is to evaluate the feasibility and safety of pterygopalatine ganglion (PPG) stimulation in adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Trial name
- NCT07570355
- Testing
- Pterygopalatine ganglion stimulation
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Shanghai Institute of Acupuncture, Moxibustion and Meridian
Age Related Macular Degeneration, Exudative Age-Related Macular Degeneration
Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration
In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.
- Conditions
- Age Related Macular Degeneration, Exudative Age-Related Macular Degeneration, Anti Vascular Endothelial Growth Factor
- Trial name
- NCT07235527
- Testing
- Aflibercept biosimilar (MY-1701P)
- Where
- Turkey (Türkiye)
- Volunteers
- 54 people
- Sponsor
- Saglik Bilimleri Universitesi
Age-Related Macular Degeneration
Progression of Early Atrophic Lesions
Early atrophic age-related macular degeneration (AMD) represents an important time window in the course of so far untreatable atrophic AMD, as patients typically experience only some degree of visual dysfunction, while being at…
- Trial name
- NCT05959005
- Testing
- No intervention
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of Utah
Macular Degeneration
Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)…
- Trial name
- NCT00845273
- Testing
- Pegaptanib sodium
- Volunteers
- 3,538 people
- Sponsor
- Pfizer
Age-Related Macular Degeneration
AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance
The goal is to conduct a cross-sectional, single timepoint study on older adults with early and intermediate AMD, and with subretinal drusenoid deposits (SDD), and those in normal health, establishing an association between dark…
- Trial name
- NCT06619405
- Testing
- Streetlab VR
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Duke University
Wet Age-related Macular Degeneration
Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.
- Trial name
- DAVIO2 (NCT05381948)
- Testing
- EYP-1901, Aflibercept 2mg/0.05mL Inj,Oph
- Where
- 67 sites in United States
- Volunteers
- 161 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Age-Related Macular Degeneration
Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)
Genetic factors of an individual patient may have an impact on Ranibizumab (Lucentis) treatment outcome in patients with Wet Age-Related Macular Degeneration (AMD).
- Trial name
- NCT01676506
- Testing
- Ranibizumab, Ranibizumab Injection
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- Russian Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.